Eli Lilly and Company (NYSE:LLY) Shares Sold by Mission Creek Capital Partners Inc.

Mission Creek Capital Partners Inc. reduced its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 56.6% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,245 shares of the company's stock after selling 1,625 shares during the period. Mission Creek Capital Partners Inc.'s holdings in Eli Lilly and Company were worth $961,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Highline Wealth Partners LLC increased its stake in Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after purchasing an additional 20 shares during the last quarter. FPC Investment Advisory Inc. raised its holdings in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $48,000. Compass Financial Services Inc purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $58,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research report on Thursday. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday. Finally, Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,000.32.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $89.48 during midday trading on Thursday, hitting $809.47. 8,693,608 shares of the stock traded hands, compared to its average volume of 3,804,592. The business's 50 day moving average price is $828.65 and its two-hundred day moving average price is $817.92. The firm has a market capitalization of $767.52 billion, a PE ratio of 69.00, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the business earned $2.58 earnings per share. The company's revenue for the quarter was up 45.2% compared to the same quarter last year. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.